Subscribe To
Xencor to present preclinical data from novel xmab® cd28 bispecific antibody programs at the american association for cancer research annual meeting 2023
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokin...
March 14, 2023, 4:31 pm
Silence therapeutics: breaking the silence on an under-the-radar mid-stage sirna platform
Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune...
March 13, 2023, 11:58 pm
This biopharma stock jumped over 250% on monday: what happened?
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical c...
March 13, 2023, 8:22 pm
Provention bio shares soar after sanofi agrees to buy company in $2.9b cash deal
French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on <...
March 13, 2023, 10:15 am
Sanofi to buy provention bio in deal worth $2.9 billion
French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on ...
March 13, 2023, 2:49 am
Labcorp (lh) focuses on high-growth areas amid currency woe
In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, ...
March 8, 2023, 12:02 pm
Annexon reports fourth quarter and year-end 2022 financial results and reiterates anticipated milestones
Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for ...
March 6, 2023, 11:30 am
Fate therapeutics to present at upcoming march investor conferences
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
March 3, 2023, 9:01 pm
Fate therapeutics to present at upcoming march investor conferences
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage ...
March 3, 2023, 4:01 pm
Shattuck labs announces participation in upcoming march conferences
AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company p...
March 1, 2023, 12:00 pm
Argenx to present at upcoming investor conferences
February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
February 27, 2023, 1:00 am
Argenx to report full year 2022 financial results and fourth quarter business update on march 2, 2023
February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of ...
February 23, 2023, 1:00 am
Travere: sparsentan approval is likely, but future is uncertain
IgA Nephropathy (IgAN) is a chronic autoimmune disease that affects the kidneys and leads to end-stage ...
February 13, 2023, 5:23 pm
Biondvax presenting at bio ceo & investor conference
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on ...
February 2, 2023, 2:15 pm
Trethera announces appointment of r. boyd quinnell to board of directors
LOS ANGELES, Jan. 18, 2023 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to develop...
January 18, 2023, 5:37 pm
Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization...
January 5, 2023, 10:00 pm
Xencor to present at the 41st annual j.p. morgan healthcare conference
MONROVIA, Calif.--( BUSINESS WIRE )--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytok...
January 4, 2023, 4:01 pm
Annexon to present at 41st annual j.p. morgan healthcare conference
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
January 4, 2023, 6:30 am
Argenx to present at 41st annual j.p. morgan healthcare conference
January 3 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of pe...
January 3, 2023, 1:00 am
Genprex boosts its diabetes gene therapy program with the license of additional technology from the university of pittsburgh
Genprex, Inc. (NASDAQ:GNPX) revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some pat...
December 15, 2022, 9:16 am